home.social

#neutralization — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #neutralization, aggregated by home.social.

  1. europesays.com/ie/339645/ Early Release – Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom – Volume 32, Number 2—February 2026 – Emerging Infectious Diseases journal #Éire #Health #IE #Ireland #MonkeypoxVirus #Mpox #MVABNVaccination #neutralization #UnitedKingdom #viruses #zoonoses

  2. Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, cell.com/heliyon/fulltext/S240

    This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

  3. Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, cell.com/heliyon/fulltext/S240

    This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

  4. Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, cell.com/heliyon/fulltext/S240

    This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

  5. Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, cell.com/heliyon/fulltext/S240

    This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

  6. Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, cell.com/heliyon/fulltext/S240

    This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

  7. #Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

    Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

    etidioh.wordpress.com/2024/11/

  8. #Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

    Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

    etidioh.wordpress.com/2024/11/

  9. #Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

    Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

    etidioh.wordpress.com/2024/11/

  10. #Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

    Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

    etidioh.wordpress.com/2024/11/

  11. #Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

    Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

    etidioh.wordpress.com/2024/11/

  12. #Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants biorxiv.org/cgi/content/short/

    We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

  13. #Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants biorxiv.org/cgi/content/short/

    We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

  14. #Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants biorxiv.org/cgi/content/short/

    We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

  15. #Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants biorxiv.org/cgi/content/short/

    We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

  16. #Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants biorxiv.org/cgi/content/short/

    We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

  17. #SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: journals.asm.org/doi/full/10.1

    Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

  18. #SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: journals.asm.org/doi/full/10.1

    Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

  19. #SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: journals.asm.org/doi/full/10.1

    Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

  20. #SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: journals.asm.org/doi/full/10.1

    Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

  21. #SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: journals.asm.org/doi/full/10.1

    Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.